Overview

A Study of Tirzepatide Concentrations at Different Injection Sites in Participants With Different Body Sizes

Status:
Completed
Trial end date:
2020-04-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including screening.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tirzepatide